Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Clearmind Medicine filed a patent application in Hong Kong for novel psychedelic compounds targeting PTSD and other mental health disorders, expanding its global intellectual property portfolio. The filing stems from an exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, covering the development and commercialization of these compounds.
Key figures
- Granted patents
- 32
- Ptsd market cagr
- 5.0%
- Ptsd market size 2025 usd
- 18.5 billion
- Ptsd market size 2035 usd
- 30.2 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.